^
BIOMARKER:

Rbsig overexpression

News
Twitter
Trials
Rbsig overexpression
HER2 Positive Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
Rbsig overexpression
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
Rbsig overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C3 – Early Trials